|
IgA NEPHROPATHY, SUSCEPTIBILITY TO, 3
|
0.400 |
GeneticVariation
|
disease |
UNIPROT |
A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy.
|
25782674 |
2015 |
|
IgA NEPHROPATHY, SUSCEPTIBILITY TO, 3
|
0.400 |
SusceptibilityMutation
|
disease |
CLINVAR |
|
|
|
|
IGA Glomerulonephritis
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
The same effect was observed in two sporadic IgAN patients carriers of wild-type SPRY2, suggesting that downregulation of the MAPK/ERK1/2 pathway represents a common mechanism leading to IgAN.
|
25782674 |
2015 |
|
IGA Glomerulonephritis
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Search for genetic association between IgA nephropathy and candidate genes selected by function or by gene mapping at loci IGAN2 and IGAN3.
|
22131235 |
2012 |
|
IGA Glomerulonephritis
|
0.320 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Lung diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Spatiotemporal alterations in Sprouty-2 expression and tyrosine phosphorylation in nitrofen-induced pulmonary hypoplasia.
|
24210189 |
2013 |
|
Cleft upper lip
|
0.300 |
Biomarker
|
disease |
CTD_human |
Stage-dependent craniofacial defects resulting from Sprouty2 overexpression.
|
17576140 |
2007 |
|
Cleft Palate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Stage-dependent craniofacial defects resulting from Sprouty2 overexpression.
|
17576140 |
2007 |
|
Craniofacial Abnormalities
|
0.300 |
Biomarker
|
group |
CTD_human |
Stage-dependent craniofacial defects resulting from Sprouty2 overexpression.
|
17576140 |
2007 |
|
Cleft palate, isolated
|
0.300 |
Biomarker
|
disease |
CTD_human |
Stage-dependent craniofacial defects resulting from Sprouty2 overexpression.
|
17576140 |
2007 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Sprouty 2 gene in mouse lung tumorigenesis.
|
15136453 |
2004 |
|
Malignant neoplasm of lung
|
0.300 |
Biomarker
|
disease |
CTD_human |
Sprouty 2 gene in mouse lung tumorigenesis.
|
15136453 |
2004 |
|
Esophageal Achalasia
|
0.200 |
Biomarker
|
disease |
MGD |
We report here that loss of the Sprouty2 gene (also known as Spry2) in mice resulted in enteric nerve hyperplasia, which led to esophageal achalasia and intestinal pseudo-obstruction.
|
15937482 |
2005 |
|
Neuronal Intestinal Dysplasia, Type B
|
0.200 |
Biomarker
|
disease |
MGD |
Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia.
|
15937482 |
2005 |
|
Neuronal intestinal pseudoobstruction
|
0.200 |
Biomarker
|
disease |
MGD |
Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia.
|
15937482 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CASC2 acts as a tumor suppressor in human malignancies serving as a ceRNA for miRNAs; Sprouty2 (SPRY2), a key antagonist of RTK signaling, also serves as a tumor suppressor.
|
29373811 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition to the promotion of proliferation and suppression of apoptosis, knockdown of FOXO3a or SPRY2 induced EMT and promoted the migration and invasion of PDAC cells via activation of the β-catenin/TCF4 pathway.
|
30691517 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mechanistic studies revealed that Sprouty homolog 2 (SPRY2) was a direct target of miR-27 and that rescuing SPRY2 expression reversed the promoting effects of miR-27 on MM cell proliferation, migration, and invasion.
|
30837325 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resistance.
|
29540470 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, SPRY2 overexpression promoted tumor propagation of low-tumorigenic U251 cells.
|
29635363 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Significant decreases in the proliferation rate, degrees of migration and invasion were noted in OCCLs with SPRY2 siRNA transfection as compared with those without SPRY2 siRNA transfection.
|
29291435 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, knockdown of SPRY2 reduced the suppressive effects of miR-23a inhibition in AGS cell proliferation, migration and invasion.
|
29805579 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
SPRY2 can antagonize FGFR2-induced proliferation and invasion via suppressing ERK phosphorylation in gastric cancer cells, indicating SPRY2 as a potential therapeutic target for gastric adenocarcinoma treatment.
|
28002800 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The dissection of the mechanism of action of SPRY2 in colon cancer cells is important to understand the upregulation of this gene in a subset of patients with this neoplasia that have poor prognosis.
|
26455323 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study reveals that SPRY2 acts as a tumor suppressor in human ovarian cancer and illustrates the underlying mechanisms that can be used as possible targets for the development of novel therapeutics.
|
27835572 |
2016 |